BackLiminatus Pharma Class A Common Stock Overview
Liminatus Pharma, Inc. Class A Common Stock

Liminatus Pharma Class A Common Stock Return on Equity

Liminatus Pharma Class A Common Stock (LIMN) has a ROE of -4165.92%, below the sector sector average of 11.3%.

Get informed when a big investor buys or sells

+ Follow

ROE

-4165.92%

Return on Equity

-4165.92%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

Liminatus Pharma Class A Common Stock (LIMN) FAQ

As of the most recent data, LIMN shows a ROE of -4165.92%. That is below the sector sector average of 11.3%. Scroll down for historical charts and peer comparison views.

The its sector sector average ROE is about 11.3%. Liminatus Pharma Class A Common Stock is at -4165.92%, which is lower that average. That is roughly 36978.9% below the sector mean. Use the comparison chart on this page to see how LIMN stacks up against individual peers as well.

Check the historical chart to see whether LIMN's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Liminatus Pharma Class A Common Stock with peers to see if the move is company-specific or sector-wide.

Besides this return on equity page, Stockcircle has Liminatus Pharma Class A Common Stock's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently -4165.92%) with ownership activity and broader fundamentals.